• Fri, September 9, 2022

Michael Ulz Maintained (YMAB) at Hold with Increased Target to $17 on, Sep 9th, 2022

Michael Ulz of Morgan Stanley, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Hold with Increased Target from $15 to $17 on, Sep 9th, 2022.

Michael has made no other calls on YMAB in the last 4 months.



There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, 0 agree with Michael's Rating of Hold.



This is the rating of the analyst that currently disagrees with Michael


  • Etzer Darout of "BMO Capital" Initiated at Buy and Held Target at $27 on, Friday, June 24th, 2022

Like: 👍